New Technology
The CoE is distinguishing itself from the life sciences programs that exist in other institutions through a unique blend of translational research, interdisciplinary resources and collaboration and commercialization activities. Building upon its rich history of discovery and cutting edge research expertise and capabilities, the CoE is geared toward converting new discoveries into commercial technologies in life sciences markets.
From Lab to Market: Interdisciplinary, Translational Research
Creating New Technologies in the Life Sciences Industry
The CoE has developed a robust network of resources to facilitate the technology transfer and commercialization process. For more information on new technology and the CoE, also see:
NEW TECHNOLOGY HIGHLIGHT
Roswell Park Technology Fuels Third Biotech Company
08/02/2007 - BUFFALO, N.Y. -- Roswell Park Cancer Institute (RPCI) and AndroBioSys, Inc. (ABS) today announced a licensing and investment agreement that gives ABS exclusive rights to patented technology held by James Mohler, MD and Gary Smith, MD
co-leaders of the Prostate Cancer Program at RPCI and founders of ABS. “Androgen deprivation therapy is the most common systemic treatment for prostate cancer; the treatment is very effective for inducing remission but those remissions last only a few years.The primary goal of ABS is to pioneer new therapeutic approaches for advanced prostate cancer that will make androgen deprivation therapy curative, not palliative,” said Dr. Mohler, who also serves as Chair of RPCI’s Department of Urologic Oncology.
AndroBioSys will focus its efforts on identifying specific targets in prostate tumors (e.g. prostate vasculature, tumor stem cells and androgen metabolism) which may be developed to improve prostate cancer treatment. Using unique human cell and tissue-based screening tools, the company will identify candidate drugs and verify their specificity and activity. ABS will negotiate license agreements with pharmaceutical companies for further clinical evaluation of these potential therapeutic agents. [View News Release]
Featured Researcher
James L. Mohler, M.D.
Prostate Program
Professor of Oncology, Roswell Park Cancer Institute;
Professor, Department of Urology, School of Medicine and Biomedical Sciences,
State University of New York at Buffalo
Dr. Mohler came to RPCI after 16 years at the University of North Carolina (UNC), and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, where he served as Associate Professor of Surgery, Associate Professor of Pathology and Laboratory Medicine, and Director of the UNC Prostate Cancer Research Program. Dr. Mohler’s research interests focus on understanding the role of the androgen receptor in the growth of prostate cancer. Clinically, he is studying the application of robot-assisted surgery for prostate removal, evaluating the role of observation for some men with prostate cancer and testing novel treatments for advanced prostate cancer...[Read On...]
News
Reception to Honor UB's Inventors, Entrepreneurs
05/04/2008 - BUFFALO, N.Y. -- The University at Buffalo and its Office of Science, Technology Transfer and Economic Outreach (STOR) will recognize the research and commercialization achievements of faculty members at the annual Inventors and Entrepreneurs Reception to be held from 4-6 p.m. May 5 in The Buffalo Club, 388 Delaware Ave...[Read On]
Study Describes Mechanism Linking Alcohol with Risk of Breast Cancer
04/30/2008 - BUFFALO, N.Y. -- The known association of alcohol consumption with an increased risk of breast cancer has been linked by researchers at the University at Buffalo to a process that causes genes that promote normal cell growth to produce proteins that precipitate unregulated cell growth, an action known as hypermethylation...[Read On...]
Visit the News Archive
Events
May 6 - Dr. Austin Clean Room Program
Don’t miss the opportunity to hear one of the world’s foremost Cleanroom and Contamination Control Experts. Dr. Austin has published six textbooks on clean rooms and personally authored each of the clean room standards adopted by ISO. This program will take place from 2-6pm Roswell Park Cancer Institute, Center for Genetics & Pharmacology, Zebro Room, 701 Ellicott Street, Buffalo, NY. Register at www.thepartnership.org/events. See flyer for more information. 
May 8 – HWI Seminar Series
Please join Dr. Michael Rossman from Purdue University for a presentation on “Symmetry and asymmetry in the control of viral assembly, maturation and infection”. Program begins at 2:30pm with a reception to follow. Series is held at the Hauptman-Woodward Institute 700 Ellicott Street, Buffalo, NY 14203.
To view the complete list of events and event details, please visit our Events page
To receive periodic News & Events emails from the COE, please join our mailing list!
